GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ... - MarketWatch by Alzheimers treatment

Mon, 27 Oct 2008 01:36:16 -0400

GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ... - MarketWatch

by Alzheimers treatment @ Mon, 27 Oct 2008 01:36:16 -0400

GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ...
MarketWatch -15 hours ago
About AFFiRiS AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently ...
Glaxo, Affiris ink $553 mln Alzheimer vaccine dealReuters
all 39 news articles